BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20682979)

  • 1. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
    Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
    Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
    Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
    Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
    Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
    Shang XB; Yu ZT; Tang P; Zhang XZ
    Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells.
    Wang Z; Liang X; Cheng Z; Xu Y; Yin P; Zhu H; Li Q; Qian X; Liu J
    Anticancer Drugs; 2013 Apr; 24(4):355-65. PubMed ID: 23426174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.
    van Huis-Tanja LH; Kweekel DM; Lu X; Franken K; Koopman M; Gelderblom H; Antonini NF; Punt CJ; Guchelaar HJ; van der Straaten T
    Mutat Res; 2014 Jan; 759():37-44. PubMed ID: 24220697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW; Wen F
    Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of excision repair cross-complementation group 1 in colorectal cancer.
    Bohanes P; Labonte MJ; Lenz HJ
    Clin Colorectal Cancer; 2011 Sep; 10(3):157-64. PubMed ID: 21855036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
    Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
    Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.
    Li W; Jie Z; Li Z; Liu Y; Gan Q; Mao Y; Wang X
    Mol Med Rep; 2014 Jun; 9(6):2423-8. PubMed ID: 24699918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.